The Acute Myeloid Leukemia (AML) market was impacted by newly diagnosed, relapsed / refractory and maintenence data presented during the American Society of Hematology (ASH) meeting in Orlando, FL.
Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for: decitabine, VIDAZA®(azacitidine), IDHIFA®(enasidenib) + azacitidine, flotetuzumab, magrolimab + azacitidine, APR-246 + azacitidine, ASTX727 (cedazuridine/decitabine) VENCLEXTA® (venetoclax), rigosertib + azacitidine.
Companies presenting data include: Otsuka, BMS, Forty Seven, Aprea Therapeutics, Abbvie, Onconova.
Get immediate access to this 60-slide report so you can make better decisions today and prepare for tomorrow.
